A new USC Stem Cell study published in the Proceedings of the National Academy of Sciences has identified key gene regulators that enable some deafened animals—including fish and lizards—to naturally regenerate their hearing. The findings could guide future efforts to stimulate the regeneration of sensory hearing cells in patients with hearing loss and balance disorders.

Led by first author Tuo Shi and co-corresponding authors Ksenia Gnedeva and Gage Crump at the Keck School of Medicine of USC, the study focuses on two cell types in the inner ear: the sensory cells that detect sound, and the supporting cells that create an environment where sensory cells can thrive.

In highly regenerative species such as fish and lizards, supporting cells can also transform into replacement sensory cells after injury—a capacity absent in humans, mice and all other mammals.

Precious few garments have been made of spider silk. In 2012, a cape and shawl made from natural spider silk were displayed at the Victoria and Albert Museum, where visitors learned that the garments were the result of a unique project that spanned eight years and involved the harvesting of silk from 1.2 million spiders. In 2019, a rather less painstaking project utilized fibroin, the protein found in natural spider silk, to fabricate an outerwear jacket, North Face’s Moon Parka. Starting with fibroin meant that silk could be sourced from genetically modified bacteria, which are easier to work with than spiders. Nonetheless, the Moon Parka, which takes its name from the word moonshot, was never meant to be mass produced. It was available by lottery for just a limited time.

Museum pieces and moonshots are hardly synonymous with “mass production.” Is there another way to generate spider silk–based textiles, one that has more commercial potential? Yes, according to Kraig Biocraft Laboratories, which uses transgenic silkworms to produce lines of recombinant spider silk. The company plans to produce up to 10 metric tons of spider silk in 2025. Production of actual spider silk lines on this scale would allow textile manufacturers to test the silk on their own equipment.

It’s not just textiles that may benefit. Recombinant spider silk’s tensile strength, weight, and durability make it attractive for myriad applications, including tissue scaffolds and sutures in the biomedical field, as well as textiles and ballistic materials.

The study revealed key insights into the variability of responses to drug use, even among individuals with identical environmental conditions.

A group of scientists at VCU Massey Comprehensive Cancer Center has revealed a new genetic code that acts like a cancer ringleader, recruiting and deploying a gang of tumor cells to incite a biological turf war by invading healthy organs and overpowering the normal cells.

This discovery— published today, Dec. 9, in Nature Biotechnology —could unveil an entirely different understanding of the origins of cancer within the body, as well as offer insight into new treatment strategies that could target the growth of tumors in their earliest stages.

The study authors have also developed an intravenous therapy that empowers healthy cells to mount an immune response and build up a defensive resistance against these invading tumor cells. This treatment has already been proven effective in ovarian tumors, but the implications of this research could be universal to all cancer types.

In August, the Food and Drug Administration (FDA) granted accelerated approval of Tecelra (afamitresgene autoleucel)— the first T-cell receptor therapy for solid tumors—for people with inoperable or metastatic synovial sarcoma. Tecelra is a gene therapy created from a patient’s own T cells. A sample of cells is removed and genetically modified to express a natural T-cell receptor that targets MAGE-A4, an antigen expressed on cancer cells. In the Phase II SPEARHEAD-1 trial, the overall response rate was 43%, and 39% of responders were still doing well a year later.

Northwestern Medicine investigators have discovered new molecular mechanisms underlying DNA repair dysregulation in prostate cancer cells, findings that may inform the development of new targeted therapies for patients that have become resistant to standard treatments, according to a recent study published in Science Advances.

Qi Cao, Ph.D., the Anthony J. Schaeffer, MD, Professor of Urology, was senior author of the study.

DNA damage is a natural occurrence in cells caused by various intercellular and external stressors. However, if left unrepaired, this damage can lead to genetic mutations that can lead to the development of different diseases, including cancer.